

# 88 - References

## References

92 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 References

1. Heres S, et al. Pharmacokinetics of olanzapine long-acting injection: the clinical perspective. *Int Clin Psychopharmacol* 2014; 29:299–312.
2. Mitchell M, et al. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia. *Clin Ther* 2013; 35:1890–1908.
3. Lauriello J, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. *J Clin Psychiatry* 2008; 69:790–799.
4. Eli Lilly and Company Limited. Summary of Product Characteristics. Zypadhera (olanzapine pamoate monohydrate) 210mg powder and solvent for prolonged release suspension for injection. 2023 (last accessed August 2024); <https://www.medicines.org.uk/emc/product/6429/smpc>.
5. Denee TR, et al. Treatment continuation and treatment characteristics of four long acting antipsychotic medications (paliperidone palmitate, risperidone microspheres, olanzapine pamoate and haloperidol decanoate) in the Netherlands. *Value Health* 2015; 18:A407.
6. Taipale H, et al. Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia—a nationwide study with 20-year follow-up. *Schizophr Bull* 2017; 44:1381–1387.
7. O’Neill JR, et al. Implementing gradual, hyperbolic tapering of long-acting injectable antipsychotics by prolonging the inter-dose interval: an in silico modelling study. *Ther Adv Psychopharmacol* 2023; 13:20451253231198463.
8. Citrome L. Long-acting injectable antipsychotics: what, when, and how. *CNS Spectr* 2021; 26:118–129.
9. Kochen SA, et al. Olanzapine postinjection delirium/sedation syndrome after long-acting olanzapine depot injection presenting to the emergency department: practical guidelines for diagnosis and management. *Emerg Med J* 2024; 41:759–763.
10. McDonnell DP, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. *BMC Psychiatry* 2010; 10:45.
11. Podgorná G, et al. Post-injection delirium/sedation syndrome: a case report and 2-year follow-up. *Am J Case Rep* 2022; 23:e937579.
12. Seebaluck J, et al. Case series profile of olanzapine post-injection delirium/sedation syndrome. *Br J Clin Pharmacol* 2023; 89:903–907.

13. Bushes CJ, et al. Olanzapine long-acting injection: review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice. *BMC Psychiatry* 2015; 15:65.
14. Meyers KJ, et al. Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study. *BJPsych Open* 2017; 3:186-192.
15. Garg S, et al. Delayed onset postinjection delirium/sedation syndrome associated with olanzapine pamoate: a case report. *J Clin Psychopharmacol* 2019; 39:523-524.
16. Eli Lilly Australia Pty Ltd. Consumer Medicine Information: ZYPREXA RELPREVV® (olanzapine pamoate monohydrate). 2024 (last accessed August 2024); <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2024--CMI-01649-1&d=20240807172310101>.
17. Pharmaco (N.Z.) Ltd. Consumer Medicine Information: ZYPREXA RELPREVV® (olanzapine pamoate monohydrate). 2023 (last accessed August 2024); <https://www.medsafe.govt.nz/consumers/cmi/z/zyprexarelprevvinj.pdf>.
18. Siskind D, et al. Monitoring for post-injection delirium/sedation syndrome with long-acting olanzapine during the COVID-19 pandemic. *Aust N Z J Psychiatry* 2020; 54:759-761.
19. Venkatesan V, et al. Postinjection delirium/sedation syndrome after 31st long-acting olanzapine depot injection. *Clin Neuropharmacol* 2019; 42:64-65.
20. Anand E, et al. A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation. *Neuropsychiatr Dis Treat* 2015; 11:1349-1357.
21. Atkins S, et al. A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection. *BMC Psychiatry* 2014; 14:7.

---

Revision #1

Created 2026-01-04 20:13:59 UTC by Omar Ayman

Updated 2026-01-04 20:13:59 UTC by Omar Ayman